Skip to content

Evaluating the effectiveness of intravenous ozonized saline in COVID-19 disease

Evaluating the effectiveness of intravenous ozonized saline in treatment of severe COVID-19 disease: A randomized Control trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200730048253N1
Enrollment
60
Registered
2020-08-08
Start date
2020-08-22
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: The intervention group will receive the Iranian national protocol treatment of Covid-19 (which include any of the following, Hydroxychloroquine or Chlroquine Phosp

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Severe cases of Covid-19 with chest CT changes in the form of peripheral uni- or bilateral ground glass opacity(s) in combination with any of the below: RR greater than 24, O2 Sat less than 93%, BP less than 90/60, decreased level of consciousness.

Exclusion criteria

Exclusion criteria: G6PD De?ciency Coagulopathies and thrombocytopenia Hx of seizure Hypothyroidism Pancreatitis Hemophilias Acute alcohol poisoning Pregnancy and breast feeding Allergy to ozone and ozonated products

Design outcomes

Primary

MeasureTime frame
Duration of hospitalization. Timepoint: Daily Since hospitalization. Method of measurement: patient's ?le.

Secondary

MeasureTime frame
Need for ICU. Timepoint: daily since hospitalization. Method of measurement: patient's ?le.;Duration of ICU stay. Timepoint: Daily since ICU stay. Method of measurement: Patient's ?le.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactnajme dareini

Ahvaz University of Medical Sciences

e24267s@gmail.com+98 61 3392 5312

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026